CA981678A - (2-imidazolin-2-ylamino) substituted - quinoxalines and-quinazolines as antihypertensive agents - Google Patents

(2-imidazolin-2-ylamino) substituted - quinoxalines and-quinazolines as antihypertensive agents

Info

Publication number
CA981678A
CA981678A CA164,361A CA164361A CA981678A CA 981678 A CA981678 A CA 981678A CA 164361 A CA164361 A CA 164361A CA 981678 A CA981678 A CA 981678A
Authority
CA
Canada
Prior art keywords
quinoxalines
quinazolines
imidazolin
ylamino
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA164,361A
Other languages
English (en)
Other versions
CA164361S (en
Inventor
Michael Snarey
John C. Danilewicz
Geoffrey N. Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp
Original Assignee
Pfizer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp filed Critical Pfizer Corp
Application granted granted Critical
Publication of CA981678A publication Critical patent/CA981678A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA164,361A 1972-02-29 1973-02-22 (2-imidazolin-2-ylamino) substituted - quinoxalines and-quinazolines as antihypertensive agents Expired CA981678A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919672A GB1381979A (en) 1972-02-29 1972-02-29 Amino derivatives of quinoline quinoxaline and quinazoline
GB5162972 1972-11-08

Publications (1)

Publication Number Publication Date
CA981678A true CA981678A (en) 1976-01-13

Family

ID=26242776

Family Applications (1)

Application Number Title Priority Date Filing Date
CA164,361A Expired CA981678A (en) 1972-02-29 1973-02-22 (2-imidazolin-2-ylamino) substituted - quinoxalines and-quinazolines as antihypertensive agents

Country Status (16)

Country Link
US (1) US3890319A (pl)
JP (2) JPS5754516B2 (pl)
AR (1) AR213705A1 (pl)
AU (1) AU471598B2 (pl)
BE (1) BE795970A (pl)
CA (1) CA981678A (pl)
CH (2) CH577500A5 (pl)
DE (1) DE2309160A1 (pl)
ES (2) ES411804A1 (pl)
FI (1) FI63757C (pl)
FR (1) FR2181776B1 (pl)
GB (1) GB1381979A (pl)
IE (1) IE37519B1 (pl)
MX (1) MX3042E (pl)
NL (1) NL159102B (pl)
SE (1) SE417204B (pl)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1463520A (en) * 1974-09-06 1977-02-02 Pfizer Ltd Process for the production of imidazolines
JPS5373571A (en) * 1976-12-10 1978-06-30 Otsuka Pharmaceut Co Ltd Carbostyril derivatives
US4188393A (en) 1977-04-22 1980-02-12 Sandoz Ltd. Treating spastic conditions or relaxing muscles
US4145421A (en) 1977-04-22 1979-03-20 Sandoz Ltd. Treating spastic conditions
FR2449087A2 (fr) * 1979-02-16 1980-09-12 Rhone Poulenc Ind Nouveaux derives de l'isoquinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent
US4486432A (en) * 1982-09-30 1984-12-04 Eli Lilly And Company Quinoxalinedione leukotriene release inhibitors
FR2541680B1 (fr) * 1983-02-24 1985-06-14 Rhone Poulenc Sante Nouveaux derives de l'amino-5 dithiole-1,2 one-3, leur preparation et les compositions medicinales qui les contiennent
JPS6118950U (ja) * 1984-07-10 1986-02-03 財団法人鉄道総合技術研究所 トロリ線の給油装置
JPS63296814A (ja) * 1987-05-29 1988-12-02 Ishigaki Kiko Kk 集塵装置における濾材の目詰り除去装置
GB8827820D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
US5180721A (en) * 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5326763A (en) * 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5198442A (en) * 1989-10-12 1993-03-30 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5204347A (en) * 1989-10-12 1993-04-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
US5112822A (en) * 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5231096A (en) * 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
US5130441A (en) * 1990-02-06 1992-07-14 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5237072A (en) * 1990-02-06 1993-08-17 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5252595A (en) * 1990-02-28 1993-10-12 Allergan, Inc. Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US6323204B1 (en) * 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
ES2187533T3 (es) * 1993-10-13 2003-06-16 Allergan Inc Usdo de derivados de (2-imidazolin-2-ilamino)quinoxalina.
US5580892A (en) * 1993-10-22 1996-12-03 Allergan Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents
US5576437A (en) * 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
BR9408342A (pt) * 1993-12-17 1997-08-19 Procter & Gamble Compostos de 6-(2-imidazolinilamino) quinoxalina úteis como agonistas de adrenoceptores de alfa-2
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5578607A (en) * 1993-12-17 1996-11-26 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
JPH09511483A (ja) * 1993-12-17 1997-11-18 ザ、プロクター、エンド、ギャンブル、カンパニー α−２−アドレノセプター作動剤として有用な６−（２−イミダゾリニルアミノ）キノリン化合物
EP0693055B1 (en) * 1994-02-08 1997-05-21 Alcon Laboratories, Inc. Novel process for preparation of clonidine derivatives
WO1996004270A1 (en) 1994-08-04 1996-02-15 Synaptic Pharmaceutical Corporation Novel benzimidazole derivatives
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5916900A (en) 1995-06-29 1999-06-29 The Procter & Gamble Company 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
KR20000069128A (ko) * 1996-11-25 2000-11-25 데이비드 엠 모이어 알파-2 아드레날린수용체 아고니스트로서 유용한 2-이미다졸리닐아미노벤즈옥사졸 화합물
NZ336010A (en) 1996-11-25 2001-05-25 Procter & Gamble Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
US6172095B1 (en) 1996-11-25 2001-01-09 The Procter & Gamble Company Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
US6306877B1 (en) 1999-08-09 2001-10-23 The Procter & Gamble Co. Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
CZ180599A3 (cs) * 1996-11-25 1999-11-17 The Procter & Gamble Company 2-Imidazolinylaminoindolová sloučenina, farmaceutický prostředek ji obsahující a její použití
WO1998023612A1 (en) * 1996-11-25 1998-06-04 The Procter & Gamble Company 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
PL340711A1 (en) 1997-11-24 2001-02-26 Procter & Gamble Derivatives of 5-(2-imidazolinamino)-benzimidazole, their production and application of them as antagonists of alpha-adrenergic receptors of improved metabolic stability
WO2004073708A1 (en) 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
RU2291685C2 (ru) 2000-07-14 2007-01-20 Аллерган Инк. Композиции, содержащие терапевтически активные компоненты, обладающие повышенной растворимостью
HUP0303197A3 (en) 2000-07-14 2008-03-28 Allergan Inc Compositions containing alpha-2 adrenergic agonist components
DE10161767A1 (de) * 2001-12-15 2003-06-26 Merck Patent Gmbh 2-Guanidino-4-heterocyclyl-chinazoline
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
NZ539328A (en) * 2002-10-08 2007-01-26 Allergan Inc Use of alpha 2B or 2B/2C adrenoceptor agonists for the treatment of Alzheimer's or Parkinson's disease
CA2501348A1 (en) * 2002-10-08 2004-04-22 Allergan, Inc. Treatment of dementia and parkinson's disease
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
AU2004263149B2 (en) * 2003-08-07 2010-08-19 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
AU2004264937B2 (en) * 2003-08-14 2010-04-29 Array Biopharma Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
WO2005039567A1 (en) * 2003-10-08 2005-05-06 Allergan, Inc. Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
MXPA06013649A (es) 2004-05-25 2007-07-09 Sansrosa Pharmaceutical Dev In Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel.
US7534795B2 (en) * 2005-10-25 2009-05-19 Allergan, Inc. Compounds and their use related to compositions for treating disease
KR20080065704A (ko) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
SI2090575T1 (sl) 2005-11-15 2011-08-31 Array Biopharma Inc Postopki in intermediati za pripravo N4-fenil-kinazolin-4-aminskih derivatov
WO2008074068A1 (en) * 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
US20080293728A1 (en) * 2007-05-18 2008-11-27 Mcintire Gregory L Complexes Comprising alpha2-Adrenergic Receptor Agonists and Compositions
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
CA2777223C (en) 2009-10-06 2017-10-24 Allergan, Inc. 2h-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
BR112012024289A2 (pt) 2010-03-26 2017-07-18 Galderma Res & Dev "método para fornecer um tratamento seguro e efetivo do eritema e composição de gel tópica"
CA2792649A1 (en) 2010-03-26 2011-09-29 Michael Graeber Improved methods and compositions for safe and effective treatment of telangiectasia
EP2555748A2 (en) 2010-04-07 2013-02-13 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
CA2796041A1 (en) 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservative compositions for ophthalmic formulations
AU2011282683B2 (en) 2010-07-29 2016-12-22 Allergan, Inc. Preservative free brimonidine and timolol solutions
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
DK2444068T4 (en) 2010-10-21 2018-03-05 Galderma Sa Brimonide sub-composition
CN103827107A (zh) 2011-07-25 2014-05-28 阿勒根公司 作为α2肾上腺素能受体的调节剂的N-(咪唑烷-2-亚基)喹啉衍生物
GR1009419B (el) 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560501A (en) * 1966-09-15 1971-02-02 Ciba Geigy Corp Process for making dihydroquinazolines
US3594380A (en) * 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
BE766039A (fr) * 1971-04-21 1971-09-16 Labofina Sa Nouveaux polymeres contenant des unites de pyrazole et procede de preparation de ces polymeres.

Also Published As

Publication number Publication date
IE37519L (en) 1973-08-29
MX3042E (es) 1980-03-04
JPS5625176A (en) 1981-03-10
AR213705A1 (es) 1979-03-15
AU471598B2 (en) 1976-04-29
AU5198573A (en) 1974-08-08
FR2181776A1 (pl) 1973-12-07
NL159102B (nl) 1979-01-15
DE2309160A1 (de) 1973-09-27
US3890319A (en) 1975-06-17
GB1381979A (en) 1975-01-29
FR2181776B1 (pl) 1976-08-13
FI63757C (fi) 1983-08-10
BE795970A (fr) 1973-08-27
JPS5754516B2 (pl) 1982-11-18
NL7302799A (pl) 1973-08-31
ES411804A1 (es) 1976-05-01
ES412102A1 (es) 1976-05-16
JPS5745439B2 (pl) 1982-09-28
SE417204B (sv) 1981-03-02
CH576975A5 (pl) 1976-06-30
JPS4897878A (pl) 1973-12-13
IE37519B1 (en) 1977-08-17
FI63757B (fi) 1983-04-29
CH577500A5 (pl) 1976-07-15

Similar Documents

Publication Publication Date Title
CA981678A (en) (2-imidazolin-2-ylamino) substituted - quinoxalines and-quinazolines as antihypertensive agents
CA984843A (en) Heterocyclic compounds
AU467511B2 (en) Dilution agent
CA1014446A (en) Perfluoralkylphosphorus compounds as foam-dampening agents
CA1000721A (en) DERIVATIVES OF .alpha.-GLUTAMYL-4-NITROANILIDE
CA978946A (en) .alpha.-ARYL-4-SUBSTITUTED PIPERIDINOALKANOL DERIVATIVES
CA980769A (en) 1,2,3-triazole derivatives
CA984838A (en) N,n'-diphenyl-n-(n"-alkylcarbamoyl) formamidine derivatives
AU470054B2 (en) Sawblade
CA990285A (en) 1,2-dihydroquinobenzoxa(or thia)zepine derivatives
CA1011340A (en) 1-aryl-5-substituted tetrazoles
CA1018458A (en) Antihypertensive hydrazinopyridazine-containing mixtures
ZA731406B (en) New antihypertensive agents
AU5707273A (en) Novel benzimidazoles
CA981666A (en) 5,11-dihydrodibenzoxa(or thia)zepine derivatives
CA924719A (en) Heterocyclic compounds
AU443984B2 (en) Amidoxime o-carbamates as antihypertensive agents
CA908051A (en) Benzimidazoles useful as antifungals
AU6592669A (en) Amidoxime o-carbamates as antihypertensive agents
CA902081A (en) Substituted benzimidazoles
CA816133A (en) Amino-alkoxy-2-naphthyl derivatives as anti-cholesteremic agents
CA889853A (en) Imidazolidinedione derivatives
CA914336A (en) Block copolymer - polypropylene compositions
CA897854A (en) N-alkyl pyrrolidone-plasticized copolylactam compositions
AU478091B2 (en) N-hetero arylmethyl-benzomorphane derivatives